In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti- Tumor Immunity

摘要

Although to our knowledge there are no dearly defined tumor antigens for prostate cancer, based on our preliminary data we of the opinion that specific gene-modified cell-based immunotherapy protocols could result in the generation of a systemic anti-metastatic immune response. We have shown that IL- 12+B7 transduced antigen-presenting cells (APC) can effectively induce an anti- tumor immunity; that IL-12+B7 modified prostate cancer cell vaccine strategies can generate a systemic anti-tumor immune response; and, that IL-12+B7 gene delivery has specific therapeutic effects against bone metastases. We proposed to test the efficacy of specific therapeutic approaches incorporating novel biological concepts of IL-12 gene modified cell-based therapy using preclinical models of metastatic prostate cancer.